Bradley closes acquisition of Bioglan

Bradley Pharmaceuticals has closed its previously-announced acquisitionof the assets of Bioglan Pharmaceuticals, a wholly-owned subsidiary of Quintiles Transnational (Marketletter June 21). The total consideration paid by Bradley at closing was around $188.3 million in cash, including inventory of about $5.4 million. Quintiles has said it intends to use the proceeds of the sale to potentially pay down debt and to fund business growth initiatives.

As part of the transaction, Bradley acquired certain intellectual property, regulatory filings and other assets relating to: Solaraze (diclofenac sodium), a 3% gel, indicated for the treatment of actinic keratoses; Adoxa (doxycycline monohydrate) tablets, an oral antibiotic indicated for the treatment of acne; Zonalon (doxepin hydrochloride), a 5% cream for the management of pruritis; TxSystems, a line of advanced topical treatments used during in-office procedures; and certain other dermatologic products.

As a result of the acquisition, Bradley's total sales force has grown to approximately 210, consisting of around 160 representatives in Doak Dermatologics and 50 representatives in Kenwood Therapeutics.